Brief: Lantern Pharma Receives Ind Clearance From FDA Enabling Phase 1 Initiation For Drug Candidate Lp-284 In Non-Hodgkin’S Lymphomas
18/09/2023 14:12
Sept 18 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA RECEIVES IND CLEARANCE FROM FDA ENABLING
PHASE 1
INITIATION FOR DRUG CANDIDATE LP-284 IN NON-HODGKIN’S LYMPHOMAS
* EXPECTS TO COMMENCE ENROLLMENT OF PATIENTS FOR
FIRST-IN-HUMAN
PHASE 1 TRIAL FOR LP-284 DURING Q4
Source text for Eikon: ID:nBw8SqSJNa
Further company coverage: LTRN.O
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview